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Abstract
Bangladesh is one of the top- ten most heavily burdened countries for viral hepatitis, with hepatitis B (HBV) infections respon-
sible for the majority of cases. Recombinant and occult HBV infections (OBI) have been reported previously in the region. We 
investigated an adult fever cohort (n=201) recruited in Dhaka, to determine the prevalence of HBV and OBI. A target- enrichment 
deep sequencing pipeline was applied to samples with HBV DNA >3.0 log
10
 IU ml−1. HBV infection was present in 16/201 (8 %), 
among whom 3/16 (19 %) were defined as OBI (HBsAg- negative but detectable HBV DNA). Whole genome deep sequences 
(WGS) were obtained for four cases, identifying genotypes A, C and D. One OBI case had sufficient DNA for sequencing, revealing 
multiple polymorphisms in the surface gene that may contribute to the occult phenotype. We identified mutations associated 
with nucleos(t)ide analogue resistance in 3/4 samples sequenced, although the clinical significance in this cohort is unknown. 
The high prevalence of HBV in this setting illustrates the importance of opportunistic clinical screening and DNA testing of 
transfusion products to minimise OBI transmission. WGS can inform understanding of diverse disease phenotypes, supporting 
progress towards international targets for HBV elimination.
INTRODUCTION
Estimates suggest that approximately a third of the world’s 
population has been exposed to hepatitis B virus (HBV), with 
chronic HBV infection (CHB) affecting more than 260 million 
individuals worldwide, leading to 800 000 deaths annually [1]. 
Ambitious elimination targets have been established, linked 
to UN Sustainable Development Goals [2]. Bangladesh has 
an intermediate CHB prevalence, estimated at 2–6 % [3, 4], 
although epidemiology varies between regions and according 
to sociodemographic factors [5]. In combination with the 
large population, this HBV prevalence puts Bangladesh in 
the top- ten highest- burdened countries for viral hepatitis 
worldwide [6], with the perinatal incidence of new infections 
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HBV prevalence estimates are typically based on HBsAg 
screening. However, this does not account for occult HBV 
infection (OBI), in which individuals are HBV DNA positive, 
but HBsAg negative (usually in combination with a positive 
anti- HBc antibody) [8]. OBI can arise in several contexts. 
Typically, when HBsAg is undetectable, corresponding 
viral loads (VL) are low (<200 IU ml−1), reflecting minimal 
production of HBsAg, or impaired egress from hepatocytes. 
A number of mutations have been linked to this low- HBsAg 
phenotype [8–10]. Occult phenotypes may also be driven 
by anti- HBs seroconversion [11, 12]. Mutations in HBsAg 
affecting antibody binding in diagnostic assays have also been 
described, meaning HBsAg is expressed but not detected 
(‘false- occult’ infections) [8]. This is pertinent for assays that 
rely on detection of the ‘a’ determinant of the small HBsAg 
protein [13]; substitutions, insertions and deletions in this 
region can result in OBI [14].
OBI has been described in Bangladesh in a range of different 
contexts [15, 16], with case reports of OBI transmission docu-
mented [17, 18]. The majority of clinical and epidemiological 
studies overlook OBI, as HBV DNA screening is expensive. 
However, recommendations for screening blood products 
increasingly include HBV DNA testing in order to avoid 
OBI transmission [19]. Recognising the high burden of HBV 
infection in Bangladesh, and limited data about OBI, we set 
out to investigate the prevalence and molecular characteristics 
of HBV and OBI in a hospital cohort.
METHODS
Study settings and clinical cohort
We screened a prospective observational fever cohort in 
Bangladesh to opportunistically study characteristics of 
HBV infection and OBI. This hospital cohort was recruited 
to examine causes of febrile illness, and it was anticipated 
that HBV infection would not be relevant to the diagnosis 
for which patients had presented. Serum samples were 
collected from adults (≥18 years of age) recruited between 
June- October 2017 at two sites:
(1) Dhaka Medical College Hospital (DMCH) is a public 
hospital, and the largest tertiary care hospital in Bangla-
desh with 2300 beds. Patients are admitted to a full range 
of specialties, and mostly receive free care.
(2) The Bangladesh Institute of Research and Rehabilita-
tion in Diabetes, Endocrine and Metabolic Disorders 
(BIRDEM), is a non- government not for profit specialist 
hospital in Dhaka with 750 beds. Baseline investigations 
are performed at a government- subsidised rate, but 
patients typically pay for specialist investigations.
Both hospitals receive patients from across the country. 
Patients from Internal Medicine, Critical Care Medicine, 
Surgery or Orthopaedics were eligible if presenting with a 
history of fever >38 °C for >48 h. As routine infant HBV vacci-
nation was not rolled out in Bangladesh until 2003, few of this 
cohort are likely to have received childhood immunisation 
against HBV.
Blood sampling and baseline screening for HBV 
infection
Serum samples were collected and screened for HBV infec-
tion and HBV exposure at local accredited testing facilities 
(Virology department of Bangabandhu Sheikh Mujib Medical 
University) in Dhaka, using HBsAg (LIAISON XL Murex 
HBsAg Quant, Italy) and total antibody to HBV core (anti-
 HBc) (LIAISON anti- HBc, Italy) respectively. All HBsAg- 
positive and anti- HBc- positive patients were screened for 
HBV DNA at the clinical diagnostic laboratory at Oxford 
University Hospitals NHS Foundation Trust (OUH), UK 
(COBAS AmpliPrep/COBAS TaqMan, Roche, Welwyn 
Garden City, UK [20]) with an automated platform to detect 
and quantify HBV DNA. HBV DNA positive samples also 
underwent HBeAg testing at OUH, when sufficient sample 
was available (Abbott Architect i2000SR).
Clinical follow-up
Patients who tested HBV positive were informed about the 
result and referred to Hepatology services for clinical assess-
ment, management and follow- up.
DNA extraction and sequencing
Serum volumes ≤0.5 ml were made available for the study. 
Samples with HBV DNA VL ≥3.0 log10 IU ml
−1 underwent 
a target- enrichment approach for HBV whole genome 
sequencing (WGS) on an Illumina Mi- Seq platform in Oxford, 
UK. This threshold is determined by the sensitivity of current 
deep sequencing approaches for WGS [21, 22]. DNA was 
extracted from serum using the NucliSENS magnetic extrac-
tion system (bioMérieux). A completion- ligation reaction 
was performed to convert the partially dsDNA genome into 
a fully dsDNA molecule [23], after which DNA was purified 
using Agencourt RNAClean XP magnetic beads (Beckman 
Coulter).
Sequencing libraries were generated using the NEBNext Ultra 
II DNA Library Prep Kit (New England Biolabs) and libraries 
were assessed using TapeStation system (Agilent) and Qubit 
dsDNA HS Assay (Thermo Fisher Scientific). An adapted 
target- enrichment workflow was applied to the SeqCap 
EZ (Roche) protocol, using custom- designed HBV probes 
ordered from IDT (xGen Lockdown Probes). Samples were 
sequenced on an Illumina Mi- Seq using a v3 300 bp paired 
end kit.
Analysis of sequence data
Deep sequencing read pairs were de- multiplexed using 
QUASR v7.01 and adapter sequences trimmed with CutAdapt 
v1.7.1 [24]. Short reads (< 50 bp length) and reads mapping 
to the human genome reference sequence (identified using 
Bowtie v2.2.4 [25] were discarded. Remaining reads were 
mapped to HBV reference sequences representing genotypes 
A- I using BWA mem v0.7.10 [26], to select the most appro-
priate reference sequence and to identify HBV reads. Reads 
were then mapped against the reference sequence using BWA 
mem and consensus sequences were derived. Simmonics 
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Sequence Editor [27] was used for alignment and sequence 
examination, using the genotype A sequence X02763 as a 
numbering reference. Maximum- likelihood phylogenetic 
analysis of consensus sequences was performed with mega7 
[28] with 1000 bootstrap replicates used. Trees were visual-
ised in Figtree [29]. Sequences were analysed with reference 
sequences [30] and 61 published full length HBV genome 
sequences from Bangladesh identified in Genbank.
We looked for evidence of dual infections in the mapping of 
reads to HBV genotypes A- I and consensus sequences were 
further checked for evidence of recombination by bootscan 
analysis using RDP4 [31].
Identification of potential resistance associated 
mutations (RAMs) and vaccine escape mutations 
(VEMs)
We referred to previously published lists of HBV RAMs for 
lamivudine (3TC) [32] and tenofovir disoproxil fumarate 
(TDF) [33]. VEMs are most commonly reported within 
the HBV surface antigen (HBsAg) ‘a’ determinant (residues 
124–147), which is the major target of neutralising antibodies. 
We therefore focused scrutiny on this region, searching for 
evidence of previously catalogued polymorphisms Q129H/R, 
M133L, F/Y134I/L/T, K141E, P142S and G145R/A [34]. We 
also added A128V, as this has been independently reported 
as a VEM in Bangladesh [35, 36].
Statistics
Data were analysed using GraphPad Prism version 7.0 (San 
Diego, CA, USA). Two- sided P values were calculated using 
the Chi- square and Fisher’s exact test for dichotomous and 
ordinal variables. Continuous variables were compared using 
one- way ANOVA and the Mann- Whitney U- test. Demo-
graphic factors and clinical characteristics were summarized 
with counts (%) for categorical variables and median (inter-




The cohort recruited 201 adults, with a median age of 35 years 
(IQR 28–55 years), of whom 115/201 (57 %) were male. Expo-
sure to HBV was common, with 72/201 (35.8 %) testing anti- 
HBc- positive (Table S1). Active HBV infection was confirmed 
in 16/201 individuals (7.9 %), comprising 10/16 who were 
positive for both HBsAg and HBV DNA (62.5 %), 3/16 posi-
tive for HBsAg with undetectable HBV DNA (18.8 %), and 
3/16 with OBI based on testing positive for HBV DNA with 
negative HBsAg (18.8 %) (Fig. S1, available in the online 
version of this article). A clinical diagnosis was available for 
all patients; leading causes of admission were enteric fever, 
urinary tract infections and septicaemia (accounting for 60 % 
of all admissions). There was no difference in reasons for 
admission between HBV- positive and negative individuals, 
and liver infection/disease was not recorded as a diagnosis 
for any patient (see Metadata Table, https:// doi. org/ 10. 6084/ 
m9. figshare. 11973930).
Characteristics of HBV infections and OBI
Median VL of the samples with detectable HBV DNA was 
2.6 log10 IU ml
−1 (IQR 1.9–5.0 log10 IU ml
−1), excluding 
one sample with a VL below the limit of quantification 
(<1.0 IU ml−1). HBeAg testing was available for 12/13 HBV 
DNA positive samples, of which 1/12 samples (8.3 %; ID 
118) was HBeAg- positive. Interestingly this HBeAg- positive 
sample was also an occult infection. HBV exposure was more 
common amongst homemakers (P=0.006) and less frequent 
in students (P=0.02), but there was no difference according 
to age or sex (Table S1). OBI arose only in males ≥60 years 
of age, which is significantly older than the age of the other 
HBV- positive subjects (Fig. 1a, P=0.02). Median HBV VL of 
the OBI cases (2.6 log10 IU ml
−1, IQR 1.1–5.3 log10 IU ml
−1) was 
comparable to VL in HBsAg- positive individuals (2.4 log10 IU 
ml−1, IQR 1.8–4.7 log10 IU ml
−1) (Fig. 1b, P=0.94). One of the 
OBI infections (sample ID 118) presented with VL 5.3 log10 IU 
ml−1, which indicates ongoing high levels of viral replication, 
despite the absence of HBsAg detection.
Identification of HBV genotypes A, C and D
We obtained full length HBV genome sequences from serum 
from all four individuals with HBV VL ≥3.0 log10 IU ml
−1, 
which included 1/3 of the OBI cases (ID 118) (Fig. 1c); the 
remaining two OBI cases had insufficient VL for WGS at 
1.1 log10 IU ml
−1 (ID 018) and 2.57 log10 IU ml
−1 (ID 034). 
Phylogenetic analysis indicated two genotype D infections, 
and one each of genotypes A and C (Fig. 2). The OBI sequence 
grouped with other genotype C sequences from Bangladesh 
(Table S2). Based on the phylogeny of full- length sequences 
and bootscan analysis, we did not find evidence of dual infec-
tion or recombination in this dataset.
The consensus sequence for sample 197 indicated a truncated 
HBV e- antigen (HBeAg) protein, based on a G1986A muta-
tion present in 57 % reads, but there was insufficient sample 
to test this sample for HBeAg. The OBI sequence (ID 118) 
and another sequence (ID 051) also expressed the truncated 
HBeAg protein as a minority variant, present in 32 % of reads 
in both samples. However, HBeAg was still detected in sample 
118 at the time of testing. This HBeAg truncation is well- 
described, associated with progression to HBeAg- negativity 
[37].
Investigation of OBI sequence polymorphisms
We examined the surface gene of OBI sample (ID 118) for the 
presence of polymorphisms previously linked to OBI [38]. 
There were no HBsAg (pre- S1, pre- S2 and S) OBI- associated 
variants in the consensus sequence. However, examining 
the deep sequencing reads, we identified several potentially 
relevant sequence changes including pre- S1 and pre- S2 dele-
tions, evidence of truncated S gene products and possible 
vaccine escape mutations in the ‘a determinant’ [38] (Fig. 3). 
4
Chowdhury et al., Journal of General Virology 2021;102:001628
Analysis indicating the most common haplotypes identified 
at each site of interest is shown in Fig. S2.
HBV RAMs VEMs
We examined consensus reverse transcriptase (RT) sequences 
for RAMs and VEMs (Table 1). RT polymorphisms A181T 
and Q215P in sample 197 have been associated with 3TC 
resistance [39]. The overlapping reading frames in HBV mean 
that the A181T mutation also results in HBsAg W172*, which 
has been associated with progressive liver disease [40].
Emerging reports suggest that RT polymorphisms can be 
associated with reduced TDF susceptibility [41]. Among 
these, L217R was present as consensus in sample 118 (55 % 
of reads) and V191I was identified as a minority variant (28 % 
reads) (Table  1). I233L was present as a minority variant 
(15 % of reads) in sample 076. The clinical significance of 
these substitutions is not well understood, but phenotypic 
resistance has most robustly been described in the presence 
of multiple RT RAMs [32, 33].
VEMs M133T and F/Y134S were present as minority variants 
in the OBI sequence. A128V, a putative VEM, was identified at 
consensus level in both our genotype D sequences. However, 
based on subgenotype (D2 for both 051 and 197), valine is 
consensus at this position.
DISCUSSION
Epidemiology of HBV and OBI infection
Our study identified HBV infection in Bangladeshi adults, 
with a prevalence of 8 % in a tertiary hospital cohort, of which 
3/16 (18.8 %) were OBI. Existing sequence data from Bang-
ladesh suggest genotypes C and D each account for ~40 % of 
the total burden, and genotype A for the remainder, with a 
Fig. 1. Characteristics of adults in Bangladesh with HBV infection, comparing those with HBsAg- positive infection to those with occult 
HBV infection and HBV sequencing coverage across the genome. (a) Ages and (b) viral load of patients with HBsAg- positive HBV and 
occult HBV infections. Median and interquartile range (IQR) are indicated. The sensitivity threshold for deep sequencing (3.0 log
10
 IU ml−1) 
is indicated in figure b with a dashed red line. Only one of the OBI cases had sufficient viral load for whole genome sequencing (ID 118). 
(c) Plot showing full length coverage of the HBV genome based on sequencing by Illumina. Sample IDs, viral loads and viral genotype 
(gt) are given for each sequence, with the OBI case highlighted. Median coverage across the genome for the samples ranged from 33 to 
77 644 reads per site. Low viral load and small sample volumes were associated with reduced coverage.
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Fig. 2. Phylogenetic tree to show the relationship between new HBV sequences and published HBV sequences from Bangladesh. 
Four full- length HBV consensus sequences generated in this study were analysed alongside HBV genotype reference sequences (for 
genotypes A- J)34 and 61 sequences originating from Bangladesh identified in online databases (unlabelled branches, Table S2). Genotype 
A sequences are highlighted in blue, genotype C in red and genotype D in yellow. The four sequences generated in this study are indicated 
with arrows; we identified one genotype C1 sequence (occult infection case, sample 118), one genotype A1 (sample 076) and two 
genotype D2 sequences (051 and 197). Genotype clades not containing Bangladesh sequences have been collapsed. Bootstrap replicates 
were repeated 1000 times, and all branches with support >70 % are indicated.
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high proportion of recombinants and mixed genotype infec-
tions [3, 5, 42]. Of note, we identified a genotype A1 isolate, 
more typically associated with transmission in Southern and 
Eastern Africa, although potentially increasingly prevalent 
in Asia [3, 5].
The lower exposure of students may reflect younger age and 
better socioeconomic backgrounds, while OBI was more 
common in older men. However, we cannot make gener-
alisations about HBV distribution in this setting, based on 
a small cohort recruited in a very specific clinical context. 
Larger studies recruiting a more generalisable population are 
required, along with the incorporation of anti- HBs screening 
to determine the impact of vaccination.
Defining and characterising OBI
Definitions of OBI vary, and identifying cases is dependent 
on the sensitivity of the platform in use for HBV DNA detec-
tion. Sequencing data from a case of OBI demonstrated a 
Fig. 3. Mutations identified in the Surface gene of sample 118 that may be linked with the OBI phenotype. The HBV surface gene is 
subdivided into three domains, pre- S1, pre- S2 and S. The proportion of reads containing polymorphisms are shown at various positions 
throughout the gene. Wt - wild- type, aa - amino acid. Deletions at the start of pre- S1 (causing truncated l- HBs proteins) and highlighted 
mutations in pre- S1 have all been associated with OBI in previous studies [38, 51, 52]. The mutated start codon of pre- S2 has been 
linked with an inability to express M- HBs [53]. The ‘a’ determinant (marked with a box at residues 124–147), is a major target of 
neutralising antibodies and widely- used target for diagnostic assays, and has a strong association with OBI mutations [10, 14, 51, 54]. 
W182* has been linked to truncated HBsAg products in OBI cases [38], and the mutation is mirrored in the reverse transcriptase gene as 
V191I (potentially linked to TDF resistance). *The short deletion observed in pre- S2 has not been reported previously and the resulting 
phenotype is unclear.
Table 1. Presence of putative Resistance Associated Mutations (RAMs) and Vaccine Escape Mutations (VEMs) in samples from four adults with chronic 
HBV infection (including one occult infection, OBI, ID 118), based on analysis of consensus level data and deep sequences generated by Illumina. 




HBV genotype RAMs (consensus 
sequence)
RAMs (frequency in deep 
sequence reads)
VEMs (consensus sequence) VEMs (frequency in deep sequence 
reads)
051* D Not present Not present A128V A128V (> 95 %)
076 A Not present I233L† (15 %) Not present Not present
118 C (OBI) L217R† V191I† (28 %)
L217R† (55%)
Not present M133T (13 %)
F/Y134S (2 6%)
197 D Not present A181T‡ (40 %) Q215P‡ (32 %) A128V A128V (> 95 %)
*Sequencing coverage in sample 051 was low (Fig. 1c), so analysis of deep sequence data in this case lacks sensitivity for detection of minor 
variants.
†Polymorphisms associated with TDF resistance.
‡Polymorphisms associated with 3TC resistance.
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combination of mutations and deletions, occurring in all 
three regions of the surface gene. None of the deletions was 
present at consensus level, illustrating the importance of deep 
sequencing data for identifying minority variants that may 
be driving uncommon phenotypes. Several of the mutations 
identified have been linked with the progression of severe 
liver disease, including W182*, thought to interfere with cell 
cycle regulation [43], typically in the context of low VL [40].
Short read sequencing provides advantages in sequencing 
depth, and deletion detection but the reconstruction of full- 
length haplotypes remains challenging, making it difficult 
to determine linkage between mutations. This question 
could potentially be addressed with longer reads that can be 
obtained through PCR and Sanger sequencing, but unfortu-
nately, we were constrained by limited sample volumes. Given 
that all mutations associated with OBI were identified only as 
minority variants; to produce an OBI phenotype this suggests 
that all genomes must carry at least one of the relevant muta-
tions, but understanding of how these mutations interact 
to produce OBI is limited. Developing sensitive long- read 
sequencing approaches for HBV remains an important aspi-
ration, enabling improved understanding of the interactions 
between different polymorphisms, and their contribution to 
disease states [44].
Evidence for drug and vaccine resistance
A previous meta- analysis of drug resistance in Bangladesh 
reported a prevalence of 3TC resistance of 11 %, but no 
TDF resistant motifs [35]. Although our cohort is small, it 
is striking that we nevertheless identified mutations linked 
to both 3TC and TDF resistance. In these treatment- naive 
patients we cannot confirm the in vivo significance of these 
RAMs, but our data do raise concern that these mutations are 
circulating; further work is needed to explore their prevalence 
and clinical significance.
Mutations in HBsAg at positions 133 and 134 are localised 
within a region known to contain major B- cell epitopes, and 
can therefore contribute to vaccine resistance [13]. A128V 
is a potential VEM, although its specific contribution to 
vaccine escape remains uncertain [45]. Previous reports of 
VEMs in Bangladesh [35], and a case report of a child [36], 
have also identified the A128V substitution, and we identified 
this variant in two of our sequences (both subgenotype D2). 
However, a subgenotype D2 reference sequence (MF925358) 
[30] has 128- valine, suggesting it is the most common residue 
in this subgenotype. This raises the possibility that subgeno-
type D2 might be more susceptible to vaccine resistance, but 
further work is required to substantiate this. The significance 
of these variants in our sequence data is uncertain, as we did 
not collect vaccine history data or measure vaccine- mediated 
antibody titres.
Caveats and limitations
We have undertaken HBV screening on only a small cohort 
and without longitudinal follow- up. Although HBV was 
presumed to be incidental to the reasons for presentation 
to hospital, we cannot exclude a selection bias. HBV infec-
tions were likely to be chronic, but we did not distinguish 
between anti- HBc IgM and IgG, so acute infection is also 
possible. Routine liver function tests were not available (and 
interpretation would have been confounded by acute illness). 
Subjects were not routinely screened for HCV, which has been 
associated with occult HBV infection and has an estimated 
prevalence of 1 % in this region [6, 46].
The study highlights the current technical challenges of 
generating whole genome deep sequencing data for HBV, for 
which a typical threshold VL is >3.0 log10 IU ml
−1 [47, 48]. 
The median VL of 2.6 log10 IU ml
−1 in this cohort illustrates 
the high proportion of cases with VL below the current 
sequencing sensitivity [48, 49]. For this reason, we gener-
ated full length sequence data in only 4/13 cases, leaving the 
majority of HBV sequences ‘under the radar’, including two 
OBI. Previous studies have indicated there can be multiple 
pathways driving occult phenotypes, including low HBsAg 
production (often in the context of correspondingly low 
VL), anti- HBs seroconversion, and ‘false- occult’ infections, 
associated with the failure of diagnostic tests [8]. Whilst the 
high VL of the OBI we sequenced may be suggestive of a 
diagnostic failure, the lack of highly sensitive sequencing 
methods for HBV limits our insight into the mechanisms 
behind the other two OBI cases. HBsAg testing is poten-
tially more sensitive for HBV detection as HBsAg can be 
detectable in the absence of HBV DNA. However, sensitivi-
ties vary between assay platforms, and both biomarkers are 
imperfect proxies for inferring disease process in the liver. 
The use of an alternative HBsAg detection assay (potentially 
lowering the HBsAg LoD down to 0.005 IU ml−1) may have 
been informative [8]. These technical challenges, along 
with a paucity of well- studied longitudinal cohorts, remain 
barriers in furthering our understanding of HBV disease 
and transmission.
Implications for policy and clinical practice
The approach we adopted demonstrates the feasibility of 
routine HBV screening for adults admitted to hospital in 
Bangladesh. Improvements in ascertainment are key to 
advancing progress towards international elimination goals 
[6], while for individual patients facilitates referral into 
appropriate clinical care. Our data also highlight the impor-
tance of continued deployment of vaccination programmes 
with a focus on infant coverage [50]. Given the high burden 
of HBV infection in Bangladesh, there is an urgent need 
to expand our understanding of population and molecular 
epidemiology, in order to strengthen advocacy, education 
and research, and to inform investment in clinical care and 
public health.
Data availability
The datasets generated during and/or analysed during the 
current study are available in the following repositories:
• GenBank accession numbers MT114170 - MT114173.
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